- Conditions
- Parkinson Disease, Early Parkinson's Disease
- Interventions
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–29
of 29
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Dexpramipexole, Cimetidine plus Dexpramipexole
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Major Depression
- Interventions
- Pramipexole, Escitalopram
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tourette Syndrome
- Interventions
- pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID, pramipexole 0.25 mg BID, pramipexole 0.0625 mg BID
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more
- Conditions
- Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
- Interventions
- Rotigotine
- Drug
- Lead sponsor
- John Winkelman, MD, PhD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts